Ivermectin

Star23

DB00602ApprovedInvestigationalVet approvedSmall moleculeAnthelmintics Antiparasitic Agents Pediculicides Scabicides and Pediculicides

Ivermectin is an anti parasite medication used to treat head lice, onchocerciasis, strongyloidiasis, ascariasis, trichuriasis, and enterobiasis. Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of Streptomyces avermitilis.

Mechanism: Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria. This binding causes an increase in the permeability of the cell membrane to chloride ions and results in hyperpolarization of the cell, leading to paralysis and death of the parasite. Ivermectin also is believed to act as an agonist of the neurotransmitter gamma-aminobutyric acid (GABA), thereby disrupting GABA-mediated central nervous system (CNS) neurosynaptic transmission. Ivermectin may also impair normal intrauterine development of O. volvulus microfilariae and may inhibit their release from the uteri of gravid female worms.
Curator reviewed
Primary indication: Administered topically, ivermectin cream is indicated for the treatment of inflammatory lesions associated with rosacea.Curator reviewed · 13 structured indications
Formula / weight: C₉₅H₁₄₆O₂₈ · 1736.185 g/mol (avg)
First approval: Canada, 2015 · United States, 1996
Code names: CD5024 · L-640471 · MK-0933 · MK-933
Brand names: Sklice
Soolantra
Stromectol

Resolves to

Compound

UNII8883YP2R6DCAS70288-86-7ChEMBLCHEMBL1200633PubChem46936176KEGGD00804

Clinical / RWD

RxNorm6069ATCD11AX22ATCP02CF01PharmGKBPA450133

Structure

InChIKeySPBDXSGPUHCETR-JFUDTMANSA-NSMILES

[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O.[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)[C@@H](C)CC)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O

Targets

Q17328glc-2G5EBR3glc-1Q25634GluClX

Transporters

P08183ABCB1P33527ABCC1Q92887ABCC2Q9UNQ0ABCG2Q9Y6L6SLCO1B1Q9NPD5SLCO1B3

What you can answer from here — as of August 31, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6TransportersSubstrate / inhibitor direction, not just membership

Listed above

791Drug interactionsStructured to mechanism, not free text

165Clinical trialsPhase, status and sponsor resolved per trial

13Structured indicationsCondition, population, route and combination as fields, not prose